Author

M. Marty

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:virus· 2 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Ma· 2 shared F. Zhang· 2 shared J. Townsend· 2 shared J. Wang· 2 shared N. Kitamura· 2 shared X. Meng· 2 shared X. ZhangiD· 2 shared Y. Chen· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

C. Ma

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Double and triple thermodynamic mutant cycles reveal the basis for specific MsbA-lipid interactions

J. Lyu, T. Zhang, M. Marty, D. Clemmer, D. H. Russell, A. Laganowsky

The paper uses native mass spectrometry and mutant cycles to study the thermodynamics of MsbA-LPS interactions, revealing entropy-driven binding and conformational changes.

bioRxiv · Jul 3, 2023Biochemistry

Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and FlipGFP-based reporter assay

Z. Xia, M. Sacco, C. Ma, J. Townsend, N. Kitamura, Y. Hu, M. Ba, T. Szeto, X. Zhang, X. Meng, F. Zhang, Y. Xiang, M. Marty, Y. Chen, J. Wang

This study identifies potent SARS-CoV-2 PLpro inhibitors through high-throughput screening and a FlipGFP-based assay, showing improved antiviral activity compared to existing compounds.

ACS Central Science · Jun 18, 2021Peer-reviewedPharmacology & Toxicology

An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity

N. Kitamura, M. D. Sacco, C. Ma, Y. Hu, J. Townsend, X. Meng, F. Zhang, X. Zhang, A. Kukuljac, M. Marty, D. Schultz, S. Cherry, Y. Xiang, Y. Chen, J. Wang

This study designs non-covalent SARS-CoV-2 Mpro inhibitors using structure-based design and Ugi-4CR reactions, identifying 23R as the most potent compound with antiviral activity.

bioRxiv · Dec 19, 2020 · PreprintPharmacology & Toxicology